New stock news | Shenqi Pharmaceuticals submits listing application to Hong Kong Stock Exchange

According to the Zhutong finance and economics APP, it was revealed by the Hong Kong Stock Exchange on June 25 that Shenqi Pharmaceutical Co., Ltd. (referred to as Shenqi Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley, CITIC Securities, and HSBC as its joint sponsors. The prospectus shows that Shenqi Pharmaceutical is a specialized medical platform oriented towards clinical value, focusing on the fields of neurology, pain management, and allergy treatment in China. They adopt a differentiated operating model, combining original drug products and innovative pipeline, selective business development opportunities, and integrated research and development, production, and commercialization capabilities. Since acquiring UCB's neurology and allergy business and related assets in China, the company has established a comprehensive integrated platform in these fields. This platform, with well-known original drug combinations such as Keppra, Vimpat, Onfi, and the recently approved Ajovy as the core, is supported by a continuously growing pipeline covering neurology, pain management, and allergy fields.